Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7

The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC). However, in terms of safety, apatinib toxicities may lead to a dose modification or treatment interruption. Therefore, proper intervention is urgently needed to help...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Death Dis
Hlavní autoři: Ma, Ling, Wang, Zhangding, Xie, Mengyan, Quan, Yunlin, Zhu, Weiyou, Yang, Fengming, Zhao, Chenhui, Fan, Yu, Fang, Na, Jiang, Huning, Wang, Qiang, Wang, Shouyu, Zhou, Jianwei, Chen, Xiaofeng, Shu, Yongqian
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058073/
https://ncbi.nlm.nih.gov/pubmed/32139670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2352-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky